CS99, all we need to do is fund BOM2 at this point. Nothing else. RVX has the experience to do that. They just completed BOM so they know how to conduct the trial.
RVX is not yet in a position to make a good deal with a BP in the best interest of its shareholders when the SPP is $0.80. The data data data from BOM shows that there is a pretty good chance that BOM2 will achieve clinical trial topline, whatever that may be. The shareholders need that (statistical topline results) to negotiate the best possible deal with whomever going forward, if we are to see reasonable return for our efforts in investing in RVX. We deserve it. First thing first.
Koo
